Jiyong Moon1, Li Shen2, Donald S Likosky3, Vikram Sood4, Reilly D Hobbs4, Peter Sassalos4, Jennifer C Romano4, Richard G Ohye4, Edward L Bove4, Ming-Sing Si5. 1. Section of Pediatric Cardiovascular Surgery, Department of Cardiac Surgery, University of Michigan Medical School, University of Michigan, C.S. Mott Children's Hospital, Ann Arbor, Michigan; Division of Congenital Heart Surgery, Department of Surgery, Baylor College of Medicine Texas Children's Hospital, Houston, Texas. 2. Section of Pediatric Cardiovascular Surgery, Department of Cardiac Surgery, University of Michigan Medical School, University of Michigan, C.S. Mott Children's Hospital, Ann Arbor, Michigan; Department of Cardiothoracic Surgery, Shanghai Jiaotong University, Shanghai Children Hospital, Shanghai, China. 3. Department of Cardiac Surgery, Section of Health Services Research and Quality, University of Michigan Medical School, University of Michigan, Ann Arbor, Michigan. 4. Section of Pediatric Cardiovascular Surgery, Department of Cardiac Surgery, University of Michigan Medical School, University of Michigan, C.S. Mott Children's Hospital, Ann Arbor, Michigan. 5. Section of Pediatric Cardiovascular Surgery, Department of Cardiac Surgery, University of Michigan Medical School, University of Michigan, C.S. Mott Children's Hospital, Ann Arbor, Michigan. Electronic address: mingsing@umich.edu.
Abstract
BACKGROUND: The influence of ventricular morphology on Fontan outcomes is controversial. OBJECTIVES: This study hypothesized that dysfunction of the single right ventricle (RV) and right atrioventricular valve regurgitation (AVVR) increases over time and adversely impacts late outcomes following a Fontan operation. A single-center retrospective study was performed. METHODS: From 1985 through 2018, 1,162 patients underwent the Fontan procedure at our center and were included in this study. Transplant and takedown free survival, ventricular, and atrioventricular valve dysfunction after Fontan were analyzed. Death or heart transplantation information was obtained from the National Death Index and the Scientific Registry of Transplant Recipients. RESULTS: The follow-up rate was 99%. Morphologic RV was present in 58% of patients. Transplant and takedown free survival were 91%, 75%, and 71% at 10 years, 20 years, and 25 years, respectively. Morphologic RV was an independent risk factor for transplant, takedown free survival (hazard ratio: 2.4; p = 0.008). The AVVR, which preceded ventricular dysfunction in most cases, was associated with the development of ventricular dysfunction after Fontan (odds ratio: 4.3; 95% confidence interval: 2.7 to 6.7; p < 0.001). Furthermore, AVVR and ventricular dysfunction progressed over time after Fontan, especially in the RV (AVVR: p < 0.0001, ventricular dysfunction: p < 0.0001). CONCLUSIONS: Morphologic RV is negatively associated with the long-term survival following the Fontan, possibly due to a tendency toward progressive AVVR and deterioration of the single ventricle function. Additional volume overload caused by AVVR may be one of the main factors accelerating the dysfunction of the single RV, implying that early valve intervention may be warranted.
BACKGROUND: The influence of ventricular morphology on Fontan outcomes is controversial. OBJECTIVES: This study hypothesized that dysfunction of the single right ventricle (RV) and right atrioventricular valve regurgitation (AVVR) increases over time and adversely impacts late outcomes following a Fontan operation. A single-center retrospective study was performed. METHODS: From 1985 through 2018, 1,162 patients underwent the Fontan procedure at our center and were included in this study. Transplant and takedown free survival, ventricular, and atrioventricular valve dysfunction after Fontan were analyzed. Death or heart transplantation information was obtained from the National Death Index and the Scientific Registry of Transplant Recipients. RESULTS: The follow-up rate was 99%. Morphologic RV was present in 58% of patients. Transplant and takedown free survival were 91%, 75%, and 71% at 10 years, 20 years, and 25 years, respectively. Morphologic RV was an independent risk factor for transplant, takedown free survival (hazard ratio: 2.4; p = 0.008). The AVVR, which preceded ventricular dysfunction in most cases, was associated with the development of ventricular dysfunction after Fontan (odds ratio: 4.3; 95% confidence interval: 2.7 to 6.7; p < 0.001). Furthermore, AVVR and ventricular dysfunction progressed over time after Fontan, especially in the RV (AVVR: p < 0.0001, ventricular dysfunction: p < 0.0001). CONCLUSIONS: Morphologic RV is negatively associated with the long-term survival following the Fontan, possibly due to a tendency toward progressive AVVR and deterioration of the single ventricle function. Additional volume overload caused by AVVR may be one of the main factors accelerating the dysfunction of the single RV, implying that early valve intervention may be warranted.
Authors: Diane E Spicer; Joseph M Bridgeman; Nigel A Brown; Timothy J Mohun; Robert H Anderson Journal: Cardiol Young Date: 2014-12 Impact factor: 1.093
Authors: Maryam Elmi; Edward J Hickey; William G Williams; Glen Van Arsdell; Christopher A Caldarone; Brian W McCrindle Journal: J Thorac Cardiovasc Surg Date: 2011-06-24 Impact factor: 5.209
Authors: Bahaaldin Alsoufi; Scott Gillespie; Dennis Kim; Subhadra Shashidharan; Kirk Kanter; Kevin Maher; Brian Kogon Journal: Ann Thorac Surg Date: 2016-06-24 Impact factor: 4.330
Authors: Timothy M Lee; Ranjit Aiyagari; Jennifer C Hirsch; Richard G Ohye; Edward L Bove; Eric J Devaney Journal: Ann Thorac Surg Date: 2011-12-23 Impact factor: 4.330
Authors: Lydia K Wright; Rachel Zmora; Yijian Huang; Matthew E Oster; Courtney McCracken; William T Mahle; Lazaros Kochilas; Andreas Kalogeropoulos Journal: Am J Cardiol Date: 2022-01-03 Impact factor: 2.778
Authors: Vojtěch Illinger; Ondřej Materna; Kryštof Slabý; Denisa Jičínská; Jan Kovanda; Karel Koubský; Jan Pokorný; Michal Procházka; Petra Antonová; Antonín Hoskovec; Jiří Radvanský; Václav Chaloupecký; Jan Janoušek Journal: ESC Heart Fail Date: 2021-12-10